Krystal Biotech, Inc. (NASDAQ:KRYS) Given Consensus Rating of “Buy” by Brokerages

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have received an average recommendation of “Buy” from the nine analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $196.75.

KRYS has been the topic of several analyst reports. Stifel Nicolaus lifted their target price on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. Chardan Capital boosted their price objective on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a report on Monday, August 5th. Citigroup reissued a “neutral” rating and set a $204.00 price objective (up previously from $195.00) on shares of Krystal Biotech in a report on Tuesday, August 6th. HC Wainwright boosted their price objective on shares of Krystal Biotech from $200.00 to $221.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. Finally, Evercore ISI boosted their price objective on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a report on Monday, August 12th.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the sale, the insider now owns 1,500,882 shares of the company’s stock, valued at $296,814,424.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 14.10% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Krystal Biotech by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 2,435,774 shares of the company’s stock valued at $302,182,000 after buying an additional 35,632 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Krystal Biotech by 54.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company’s stock valued at $117,189,000 after buying an additional 231,255 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Krystal Biotech by 1.3% in the second quarter. Dimensional Fund Advisors LP now owns 580,452 shares of the company’s stock valued at $106,593,000 after buying an additional 7,537 shares during the last quarter. Hood River Capital Management LLC raised its position in shares of Krystal Biotech by 5.1% in the second quarter. Hood River Capital Management LLC now owns 521,093 shares of the company’s stock valued at $95,694,000 after buying an additional 25,507 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in Krystal Biotech by 23.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 228,053 shares of the company’s stock worth $28,292,000 after purchasing an additional 43,709 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Stock Down 0.2 %

Shares of NASDAQ:KRYS opened at $184.17 on Monday. The company has a market cap of $5.26 billion, a price-to-earnings ratio of 98.49 and a beta of 0.82. The firm’s 50-day simple moving average is $195.14 and its 200-day simple moving average is $179.47. Krystal Biotech has a fifty-two week low of $93.95 and a fifty-two week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, August 5th. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.03. The business had revenue of $70.28 million for the quarter, compared to the consensus estimate of $65.27 million. Krystal Biotech had a net margin of 63.73% and a return on equity of 1.99%. The business’s quarterly revenue was up 70283900.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.25) earnings per share. On average, research analysts forecast that Krystal Biotech will post 3.13 EPS for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).